202 related articles for article (PubMed ID: 28554272)
21. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
22. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
23. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2
Machado-Neto JA; Coelho-Silva JL; Santos FPS; Scheucher PS; Campregher PV; Hamerschlak N; Rego EM; Traina F
Invest New Drugs; 2020 Jun; 38(3):733-745. PubMed ID: 31286322
[TBL] [Abstract][Full Text] [Related]
24. Probable HLA-mediated immunoediting of JAK2 V617F-driven oncogenesis.
Ivanova M; Tsvetkova G; Lukanov T; Stoimenov A; Hadjiev E; Shivarov V
Exp Hematol; 2020 Dec; 92():75-88.e10. PubMed ID: 33017633
[TBL] [Abstract][Full Text] [Related]
25. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
26. JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.
Ar MC; Hatemi G; Ekizoğlu S; Bilgen H; Saçli S; Buyru AN; Soysal T; Ülkü B; Yazici H
Clin Appl Thromb Hemost; 2012 Jul; 18(4):421-6. PubMed ID: 22203033
[TBL] [Abstract][Full Text] [Related]
27. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
[TBL] [Abstract][Full Text] [Related]
28. Angiogenic factors are increased in circulating granulocytes and CD34
Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Nienhold R; Diklić M; Djikić D; Leković D; Bulat T; Marković D; Gotić M; Noguchi CT; Schechter AN; Skoda RC; Čokić VP
Mol Carcinog; 2017 Feb; 56(2):567-579. PubMed ID: 27341002
[TBL] [Abstract][Full Text] [Related]
29. [Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].
Zhang Y; Li L; Nie L; Yu Y; Yang YH; Zhang ZQ; Yang L; Xu SC; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):105-9. PubMed ID: 18681311
[TBL] [Abstract][Full Text] [Related]
30. Targeting glutamine metabolism in myeloproliferative neoplasms.
Zhan H; Ciano K; Dong K; Zucker S
Blood Cells Mol Dis; 2015 Oct; 55(3):241-7. PubMed ID: 26227854
[TBL] [Abstract][Full Text] [Related]
31. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
[TBL] [Abstract][Full Text] [Related]
32. Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.
Kim HR; Choi HJ; Kim YK; Kim HJ; Shin JH; Suh SP; Ryang DW; Shin MG
PLoS One; 2013; 8(1):e52518. PubMed ID: 23349688
[TBL] [Abstract][Full Text] [Related]
33. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
[TBL] [Abstract][Full Text] [Related]
34. Metformin exerts multitarget antileukemia activity in JAK2
Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
[TBL] [Abstract][Full Text] [Related]
35. Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.
Alghasham N; Alnouri Y; Abalkhail H; Khalil S
Int J Lab Hematol; 2016 Feb; 38(1):34-41. PubMed ID: 26361084
[TBL] [Abstract][Full Text] [Related]
36. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
[TBL] [Abstract][Full Text] [Related]
37. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
38. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.
Ma W; Kantarjian H; Zhang X; Wang X; Zhang Z; Yeh CH; O'Brien S; Giles F; Bruey JM; Albitar M
PLoS One; 2010 Aug; 5(8):e12165. PubMed ID: 20730051
[TBL] [Abstract][Full Text] [Related]
39. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.
Merker JD; Jones CD; Oh ST; Schrijver I; Gotlib J; Zehnder JL
J Mol Diagn; 2010 Jan; 12(1):58-64. PubMed ID: 19959796
[TBL] [Abstract][Full Text] [Related]
40. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V
Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
